PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
May 6, 2025 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – PlaqueTec, biomarkers, clinical trials, coronary artery disease, precision medicine
- Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries
- Safety and functionality data for the updated Liquid Biopsy System supports continuation of the BIOPATTERN trial.
6 May 2025 — Cambridge, UK — PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced new research findings from interim data analysis of its ongoing BIOPATTERN trial. The findings provide early confidence in PlaqueTec’s approach to endotype CAD as the BIOPATTERN trial progresses.
Early insights into the data analysis following the collection of peri-plaque blood samples from 33 of the first 34 patients enrolled in the BIOPATTERN trial has revealed distinct protein gradients in diseased coronary artery blood compared with systemic blood. The analysis also revealed differences in protein concentration between samples taken simultaneously upstream and downstream of coronary plaque, providing early evidence that this approach can detect proteins concentrating at sites of coronary plaque. Collection of the first patient samples also confirms the safety profile of PlaqueTec’s Liquid Biopsy System™, used to collect the samples, supporting continuation of the BIOPATTERN trial.
The BIOPATTERN trial is designed to investigate trans-plaque protein signals in coronary blood samples from patients undergoing a percutaneous coronary intervention (PCI) procedure. Using the data analysed from the thousands of proteins and other blood molecules measured in each sample, PlaqueTec aims to generate novel site-of-disease insights to improve understanding of mechanisms involved in CAD progression towards heart attack. The findings will be integrated into a new data platform, which will be used to inform patient stratification and therapeutic development programmes to enable a precision medicine approach to CAD.
These latest findings from the BIOPATTERN trial will be presented at the European Atherosclerosis Society 93rd Congress, 4-7 May, 2025 (poster #369).
Dr Diane Proudfoot, Chief Scientific Officer, PlaqueTec, commented: “The current approach to treating CAD involves standardised risk-factor management, leaving many patients vulnerable and at risk of progression towards heart attack. Our approach aims to establish disease-specific treatments to address the residual risk and improve outcomes for patients with CAD. Continuation of the BIOPATTERN trial will allow us to generate a more detailed picture of the pathobiology of CAD, by uniquely sampling blood from the disease microenvironment, to identify distinct disease endotypes and enable the development of precision medicines.”
Dr Simon Williams, General Manager, PlaqueTec, added: “The interim analysis marks a key milestone in our ongoing BIOPATTERN trial. The safety profile of the LBS and high-quality of samples collected so far, and the novel site-of-disease insights generated, provides us with confidence in our approach as we progress towards the 300-patient target.”
To learn more about the BIOPATTERN trial, please visit https://www.plaquetec.com/our-research.
About PlaqueTec
PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients. The Company is based at the world-renowned Babraham Research Campus, Cambridge, UK. Visit: www.plaquetec.com.
